Next-gen CAR T cells show promise at treating solid tumors, USC study shows

The evolution of cellular immunotherapy: From transplant to CAR T cells

Nearly five decades ago, I joined City of Hope’s nascent bone marrow transplant (BMT) program, which focused on improving outcomes for patients with advanced leukemia.

FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy

FDA has granted Fast Track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma following two or more lines of prior therapy and relapsed/refractory chronic lymphocytic leukemia following two or more lines of prior therapy.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Sept. 19 for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab.

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.

September 19, 2025

Vol.51 No.34